1-20 of 60
Dennis J. Slamon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB197: Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies

Neil A. O'Brien, Holly K. Huang, Martina S. McDermott, Athena Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB197.
DOI: https://doi.org/10.1158/1538-7445.AM2022-LB197
Published: 15 June 2022
View article
Journal Articles

Abstract 342: Development and characterization of a novel anti-CLDN6 antibody drug conjugate for the treatment of CLDN6 positive cancers

Martina S. McDermott, Ke Wei Gong, Neil A. O'Brien, Dylan Conklin, Benjamin Hoffstrom, Ming Lu, Jun Zhang, Tong Luo, Weiping Jia, Jenny J. Hong, Kevin Chau, Simon Davenport, Michael F. Press, Abram Handly-Santana, Joan S. Brugge, Ronny Drapkin, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 342.
DOI: https://doi.org/10.1158/1538-7445.AM2022-342
Published: 15 June 2022
View article
Journal Articles

Abstract 2336: Pan-cancer analysis of NAMPT inhibitors reveals unique sensitivities to multiple NAMPT inhibitors in several cancer types

Jenny J. Hong, Martina S. McDermott, Jewel K. Ng, Prita Pandya, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2336.
DOI: https://doi.org/10.1158/1538-7445.AM2022-2336
Published: 15 June 2022
View article
Journal Articles

Abstract 3023: Fatty acid synthase (FASN) inhibitors synergize with carfilzomib (CFZ) in acute myeloid leukemia (AML) and multiple myeloma (MM)

Maoyu Peng, Sanaz Noelle Ghafouri, Martina SJ McDermott, Dennis J. Slamon, Sarah M. Larson
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3023.
DOI: https://doi.org/10.1158/1538-7445.AM2022-3023
Published: 15 June 2022
View article
Journal Articles

Abstract 332: Development of a novel therapeutic CLDN18.2 monoclonal antibody and antibody drug conjugate for the treatment of CLDN18.2 positive cancers

Neil A. O'brien, Martina S. McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin G. Hoffstrom, Dylan Conklin, Tong Luo, Kevin Chau, Min Liang, Timothy R. Donahue, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 332.
DOI: https://doi.org/10.1158/1538-7445.AM2022-332
Published: 15 June 2022
View article
Journal Articles

Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET

Maggie Cheang, Mitch Dowsett, Mothaffar Rimawi, Stephen Johnston, Samuel Jacobs, Judith Bliss, Katherine Pogue-Geile, Lucy Kilburn, Zhou Zhu, Eugene F. Schuster, Hui Xiao, Lisa Swaim, Shibing Deng, Dongrui R. Lu, Eric Gauthier, Jennifer Tursi, Dennis J. Slamon, Hope S. Rugo, Richard S. Finn, Yuan Liu
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD2-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD2-07
Published: 15 February 2022
View article
Journal Articles

Abstract PD12-06: Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial

Sara A Hurvitz, Rodrigo Fresco, Karen Afenjar, Daniil Stroyakovskiy, Chiun-Sheng Huang, Hans Wildiers, Kyung Hae Jung, Jean-François Boileau, Mario Campone, Miguel Martín, Vicente Valero, Joseph A. Sparano, W. Fraser Symmans, Peter A. Fasching, Alastair M. Thompson, Nadia Harbeck, Vanesa López-Valverde, Chunyan Song, Thomas Boulet, Eleonora Restuccia, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD12-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PD12-06
Published: 15 February 2021
View article
Journal Articles

Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Valerie M. Jansen, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Resel Pereira, Matteo Benelli, Ilenia Migliaccio, Luca Malorni, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Rinath Jeselsohn, Kent Osborne, Rachel Schiff
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS2-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-GS2-01
Published: 15 February 2020
View article
Journal Articles

Abstract P4-10-12: Characterizing the tumor and immune microenvironment through treatment to predict response to neoadjuvant HER2-targeted therapy using the Digital Spatial Profiler

Katherine Lee McNamara, Jennifer L. Caswell-Jin, Zhicheng Ma, Jason J. Zoeller, Michelle Kriner, Zoey Zhou, Jason Reeves, Margaret Hoang, Joseph Beechem, Dennis J. Slamon, Michael F. Press, Joan Brugge, Sara A. Hurvitz, Christina Curtis
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P4-10-12.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P4-10-12
Published: 15 February 2020
View article
Journal Articles

Abstract P4-07-01: Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial

Jennifer L. Caswell-Jin, Katherine L. McNamara, Judy Dering, Hsiao-Wang Chen, Robert Dichmann, Alejandra Perez, Ravindranath Patel, Eran Kotler, Jason J. Zoeller, Joan S. Brugge, Michael F. Press, Dennis J. Slamon, Christina Curtis, Sara A. Hurvitz
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P4-07-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P4-07-01
Published: 15 February 2020
View article
Journal Articles

Abstract P2-05-07: Pan-cancer analysis of PARP inhibition reveals a suite of biomarkers that correlate with PARP1/2 activity in breast cancer

Martina SJ McDermott, Dylan F Conklin, Neil A O'Brien, Kevin Chau, Dennis J Slamon
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P2-05-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P2-05-07
Published: 15 February 2020
View article
Journal Articles

Abstract 2978: Clinical evaluation of lapatinib induced BCL-2 adaptive responses

Jason J. Zoeller, Sara A. Hurvitz, Michael F. Press, Laura M. Selfors, Judy Dering, Dennis J. Slamon, Joan S. Brugge
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2978.
DOI: https://doi.org/10.1158/1538-7445.AM2019-2978
Published: 01 July 2019
View article
Journal Articles

Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models

Neil A. O'Brien, Martina SJ McDermott, Dylan F. Conklin, Alex Gaither, Tong Luo, Raul Ayala, Suruchi Salgar, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3825.
DOI: https://doi.org/10.1158/1538-7445.AM2019-3825
Published: 01 July 2019
View article
Journal Articles

Abstract 136: Phospho-S6 levels correlate with response to Copanlisib (BAY 80-6946) in multiple myeloma

Sarah Larson, Mao Yu Peng, Monica Mead, Andrae Vandross, Dylan Conklin, Erika Von Euw, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 136.
DOI: https://doi.org/10.1158/1538-7445.AM2017-136
Published: 01 July 2017
View article
Journal Articles

Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy

Neil A. O'Brien, Dylan Conklin, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ondrej Kalous, Erika Von Euw, Sara A. Hurvitz, Emmanuelle DiTomaso, Faye Su, Ronald Linnartz, Stefan Scherer, Samit Hirawat, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4150.
DOI: https://doi.org/10.1158/1538-7445.AM2017-4150
Published: 01 July 2017
View article
Journal Articles

Abstract CT011: Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies

Zev A. Wainberg, J. Randolph Hecht, Gottfried E. Konecny, Jonathan W. Goldman, Saeed Sadeghi, Bartosz Chmielowski, Arun Singh, Richard S. Finn, Diego Martinez, Lisa Yonemoto, John Glaspy, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT011.
DOI: https://doi.org/10.1158/1538-7445.AM2016-CT011
Published: 15 July 2016
View article
Journal Articles

Abstract CT066: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors

Philippe L. Bedard, David W. Cescon, Graham Fletcher, Trish Denny, Richard Brokx, Peter Sampson, Mark R. Bray, Dennis J. Slamon, Tak W. Mak, Zev A. Wainberg
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT066.
DOI: https://doi.org/10.1158/1538-7445.AM2016-CT066
Published: 15 July 2016
View article
Journal Articles

Abstract 1206: Preclinical evaluation of targeting Notch-3 in breast cancer

Sara A. Hurvitz, Erika von Euw, Neil O’Brien, Dylan Conklin, Chuhong Hu, Jiaying Zhuo, Alice Zhao, Frank Calzone, Hsiao-Wang Chen, Judy Dering, Ken Geles, Puja Sapra, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1206.
DOI: https://doi.org/10.1158/1538-7445.AM2016-1206
Published: 15 July 2016
View article
Journal Articles

Abstract 2736: Regulation of cytokinesis by polo-like kinase 4

Michael F. Press, Bin Xie, Simon Davenport, Yu Zhou, Neil O’Brien, Michael Palazzolo, Tak Mak, Joan Brugge, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2736.
DOI: https://doi.org/10.1158/1538-7445.AM2016-2736
Published: 15 July 2016
View article
Journal Articles

Abstract 2828: Preclinical activity of abemaciclib as a single agent or in combination with anti-mitotic or targeted therapies for breast cancer

Neil A. O’Brien, Dylan Conklin, Tong Luo, Ondrej Kalous, Erika von Euw, Sara A. Hurvitz, Richard P. Beckmann, Colleen Mockbee, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2828.
DOI: https://doi.org/10.1158/1538-7445.AM2016-2828
Published: 15 July 2016
View article